Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes

ClinicalTrials.gov ID: NCT01106040

Public ClinicalTrials.gov record NCT01106040. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 10:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Prospective, Open-Label, Multicenter Comparison Study of Lymphoseek® and Vital Blue Dye as Lymphoid Tissue Targeting Agents in Patients With Known Melanoma or Breast Cancer Who Are Undergoing Lymph Node Mapping

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Data from this pivotal clinical trial will be used to support a marketing application (i.e., NDA) of Navidea's Lymphoseek for use in anatomical delineation of lymphoid tissue (nodes) in the lymphatic pathway draining the primary site of a tumor. Multicenter, open-label, within-patient comparative study of Lymphoseek and vital blue dye in the detection of excised lymph nodes in patients with known melanoma and breast cancer. All patients will receive a single dose of 50 µg Lymphoseek radiolabeled with 0.5 or 2.0 mCi Tc 99m and vital blue dye.

Study identification

NCT ID
NCT01106040
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Navidea Biopharmaceuticals
Industry
Enrollment
163 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 2010 (Type not available)
Primary completion
Apr 2011 (Actual)
Completion
Apr 2011 (Actual)
Last update posted
Jun 17, 2013

2010 – 2011

United States locations

U.S. sites
8
U.S. states
4
U.S. cities
7
Facility City State ZIP Site status
University of Alabama, Birmingham Birmingham Alabama 35294 —
UCSD Moores Cancer Center La Jolla California 92093 —
Califonia Pacific Medical Center San Francisco California 94115 —
John Wayne Cancer Institute Santa Monica California 90404 —
H. Lee Moffitt Cancer Center Tampa Florida 33612 —
University Hospitals Cleveland Cleveland Ohio 44106 —
Breast Care Specialists Columbus Ohio 43081 —
The Ohio State University Columbus Ohio 43210 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01106040, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 17, 2013 · Synced Oct 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01106040 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →